Ewing's Sarcoma
ICD-10 C40 · ICD-11 2B52

Ewing's Sarcoma: Next-Line Management When VDC/IE Chemotherapy Has Not Achieved the Required Response

This protocol addresses patients with Ewing's sarcoma who have completed first-line compressed-interval VDC/IE chemotherapy but have not met the required histological or imaging response thresholds. It defines the structured approach for the subsequent treatment step.

First-Line Failure Condition

First-line treatment consisted of compressed interval two-weekly VDC/IE chemotherapy for 14 cycles — vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide — together with surgical resection of the primary tumour and/or radiotherapy for local control. Escalation to this protocol is indicated when that treatment fails to achieve histological necrosis greater than 90% in the resected specimen or adequate tumour volume reduction on MRI.

Treatment Goal at This Stage

The primary measure of success is tumour response on imaging after four cycles of chemotherapy.

Treatment Approach — Partial Overview

The protocol involves selection among systemic chemotherapy regimens based on efficacy and individual toxicity profiles, with high-dose consolidation followed by stem cell rescue considered in carefully selected patients — full regimen details are available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens
References

DOI: 10.1038/s41416-024-02868-4

Multiple pairwise comparisons between arms have defined the following hierarchy based on EFS, OS and RECIST 1.1 imaging response after four cycles of chemotherapy, in order of decreasing efficacy: high dose ifosfamide, topotecan and cyclophosphamide, irinotecan and temozolomide, and gemcitabine and docetaxel.

The difference in absolute EFS and OS between topotecan/cyclophosphamide and irinotecan/temozolomide is small and there are significant differences in the toxicity profiles of each regimen, with a preponderance of myelotoxicity and neutropenic fever with ifosfamide and topotecan/cyclophosphamide, a small rate of significant encephalopathy and renal toxicity with ifosfamide and gastrointestinal toxicity with irinotecan/temozolomide.

High-dose chemotherapy followed by autologous stem cell rescue has not been evaluated in a randomised trial.

Several observational studies suggest a benefit in selected patients; it may be considered as consolidation therapy in the context of no or minimal residual disease, but its use remains controversial.

View source ↗